Platelet Dysfunction Associated With Insulin Therapy in Patients With Type 2 Diabetes: Please Do Not Throw the Baby Out With the Bathwater!

Journal of the American College of Cardiology

Volumn 49, Issue 5, 2007, Pages 628-

  Scheen, André J ^a   Legrand, Delphine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEMOGLOBIN A1C; INSULIN;

ANTICOAGULANT THERAPY; COMORBIDITY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; INSULIN TREATMENT; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; THROMBOSIS;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 33846610008     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.11.004     Document Type: Letter

References (9)

1. Angiolillo D.J., Bernardo E., Ramirez C., et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48 (2006) 298-304
2. Bhatt D.L., Fox K.A.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
3. Scheen A.J., and Lefèbvre P.J. Insulin resistance vs. insulin deficiency: which comes first? The old question revisited. In: Di Mario U., Leonetti F., Pugliese G., Sbraccia P., and Signore A. (Eds). Diabetes in the New Millennium (2000), Wiley, New York, NY 101-113
4. Kahn S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46 (2003) 3-19
5. Ferrannini E., Natali A., Bell P., et al. Insulin resistance and insulin secretion in obesity. J Clin Invest 100 (1997) 1166-1173
6. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
7. Watala C., Boncler M., and Gresner P. Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep 57 Suppl (2005) 42-58
8. Muis M.J., Bots M.L., Grobbee D.E., and Stolk R.P. Insulin treatment and cardiovascular disease: friend or foe? A point of view. Diabet Med 22 (2005) 118-126
9. American Diabetes Association. Standards of medical care in diabetes mellitus-2006. Diabetes Care 29 Suppl 1 (2006) S4-S42